NEWS22 February 2010
All MRS websites use cookies to help us improve our services. Any data collected is anonymised. If you continue using this site without accepting cookies you may experience some performance issues. Read about our cookies here.
NEWS22 February 2010
US— The proliferation of laws in the US requiring disclosure of money spent by drugs companies on marketing to doctors is causing headaches for many in the research industry
IMS has launched a new set of services in the area of “aggregate spend compliance” allowing pharmaceuticals and medical device manufacturers to track, monitor and report their promotional outlays.
To date 20 states have introduced legislation requiring the disclosure of corporate gifts given to doctors. Federal legislation is also being considered, while in Vermont gifts have been banned altogether.
Problems occur for researchers when the definition of ‘marketing’ in these laws is broad enough to encompass payments for survey incentives, making it difficult if not impossible to recruit doctors and other healthcare professionals to take part in studies.
Research industry bodies including the Marketing Research Association and the Council of American Survey Research Organisations have had some success in securing clarifications to laws in Massachusetts and Minnesota so as to exempt survey incentives.
0 Comments